Hermann Einsele

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial